1.

Number of Salmonella cases per 100 000 inhabitants reported by the National Reference Center (NRC) per region, Belgium, 2016–2020.

2.

Number of Salmonella cases per 100 000 inhabitants reported by the National Reference Center (NRC) per region, Belgium, 2016–2020.

3.

Number of Salmonella cases per 100 000 inhabitants reported by the National Reference Center (NRC) per region, Belgium, 2016–2020.

4.

Number of Salmonella cases per 100 000 inhabitants reported by the National Reference Center (NRC) per region, Belgium, 2016–2020.

5.

Number of Salmonella cases per 100 000 inhabitants reported by the National Reference Center (NRC) per region, Belgium, 2016–2020.

1.

Number of Salmonella cases in the National Reference Center (NRC) database (solid line) and the Sentinel Network of Laboratories (SNL) database (dotted line), Belgium, 2016–2020.

2.

Number of Salmonella cases in the National Reference Center (NRC) database (solid line) and the Sentinel Network of Laboratories (SNL) database (dotted line), Belgium, 2016–2020.

3.

Number of Salmonella cases in the National Reference Center (NRC) database (solid line) and the Sentinel Network of Laboratories (SNL) database (dotted line), Belgium, 2016–2020.

4.

Number of Salmonella cases in the National Reference Center (NRC) database (solid line) and the Sentinel Network of Laboratories (SNL) database (dotted line), Belgium, 2016–2020.

5.

Number of Salmonella cases in the National Reference Center (NRC) database (solid line) and the Sentinel Network of Laboratories (SNL) database (dotted line), Belgium, 2016–2020.

1.

Linking peripheral laboratory sites that sent isolates to the National Reference Center (NRC) with licensed medical laboratories that were invited to the survey to estimate the cov...

2.

Linking peripheral laboratory sites that sent isolates to the National Reference Center (NRC) with licensed medical laboratories that were invited to the survey to estimate the cov...

3.

Linking peripheral laboratory sites that sent isolates to the National Reference Center (NRC) with licensed medical laboratories that were invited to the survey to estimate the cov...

4.

Linking peripheral laboratory sites that sent isolates to the National Reference Center (NRC) with licensed medical laboratories that were invited to the survey to estimate the cov...

5.

Linking peripheral laboratory sites that sent isolates to the National Reference Center (NRC) with licensed medical laboratories that were invited to the survey to estimate the cov...

1.

Coverage of the NRC surveillance system per licensed laboratory, per region, Belgium, 2019.

2.

Coverage of the NRC surveillance system per licensed laboratory, per region, Belgium, 2019.

3.

Coverage of the NRC surveillance system per licensed laboratory, per region, Belgium, 2019.

4.

Coverage of the NRC surveillance system per licensed laboratory, per region, Belgium, 2019.

5.

Coverage of the NRC surveillance system per licensed laboratory, per region, Belgium, 2019.

1.

Coverage of the NRC surveillance system as estimated through a capture-recapture study, 2016–2020, Belgium.

2.

Coverage of the NRC surveillance system as estimated through a capture-recapture study, 2016–2020, Belgium.

3.

Coverage of the NRC surveillance system as estimated through a capture-recapture study, 2016–2020, Belgium.

4.

Coverage of the NRC surveillance system as estimated through a capture-recapture study, 2016–2020, Belgium.

5.

Coverage of the NRC surveillance system as estimated through a capture-recapture study, 2016–2020, Belgium.

1.

A two-source capture-recapture analysis to estimate the ‘true’ number of Salmonella cases in Belgium, 2016–2020.

2.

A two-source capture-recapture analysis to estimate the ‘true’ number of Salmonella cases in Belgium, 2016–2020.

3.

A two-source capture-recapture analysis to estimate the ‘true’ number of Salmonella cases in Belgium, 2016–2020.

4.

A two-source capture-recapture analysis to estimate the ‘true’ number of Salmonella cases in Belgium, 2016–2020.

5.

A two-source capture-recapture analysis to estimate the ‘true’ number of Salmonella cases in Belgium, 2016–2020.

1.

Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015.

2.

Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015.

3.

Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015.

1.

First interception of Aedes (Stegomyia) albopictus in Lucky bamboo shipments in Belgium

2.

First interception of Aedes (Stegomyia) albopictus in Lucky bamboo shipments in Belgium

3.

First interception of Aedes (Stegomyia) albopictus in Lucky bamboo shipments in Belgium

4.

First interception of Aedes (Stegomyia) albopictus in Lucky bamboo shipments in Belgium

5.

First interception of Aedes (Stegomyia) albopictus in Lucky bamboo shipments in Belgium

1.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

2.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

3.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

4.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

5.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

6.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

7.

Haemolytic uremic syndrome surveillance in children less than 15Â years in Belgium, 2009-2015.

1.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

2.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

3.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

4.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

5.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

6.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

7.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

8.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

9.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.